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Executive summary 
and recommendations
Pharmacological treatment is an important component of much 
of psychiatric practice. Many psychotropic medications and 
psychological interventions are available for patients with mental 
health problems, but patients often remain troubled by distressing 
symptoms despite undergoing a series of pharmacological and 
psychological treatments. In this situation, doctors may wonder 
whether they might prescribe a medication outside the narrow 
terms of its market authorisation (‘product licence’) in an attempt 
to improve clinical outcomes. Many authorities agree that use of 
a drug outside the terms of its licence can be a necessary and 
beneficial part of clinical practice, whereas others have raised 
concerns about patient safety and medical liability. 
The Royal College of Psychiatrists first issued guidance on 
recommended procedures for the use of licensed medicines 
for unlicensed applications in psychiatric practice in 2007. In 
the subsequent decade, evidence on this aspect of practice 
has increased and other bodies have also provided guidance 
(e.g. General Medical Council, 2013). The Royal College of 
Psychiatrists’ Psychopharmacology Committee was therefore 
asked to consider and, if necessary, revise current College 
guidance and did so in consultation with representatives from 
the British Association for Psychopharmacology (BAP). We 
considered the potential benefits and risks of this aspect of 
clinical practice and believe that prescription of a drug outside the 
narrow terms of its market authorisation can be an appropriate 
part of overall management and in the best interests of a patient. 
The Committee strived to make ten balanced recommendations 
that it judged would be feasible to implement within current 
psychiatric practice. 
Recommendations
1. First check that medicines with a licence (market 
authorisation) for the particular indication have either had 
an adequate therapeutic trial or have been considered 
carefully but excluded on clinical grounds (such as treatment 
contraindications or risk of drug–drug interactions).
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2. Become familiar and be satisfied with the evidence base 
for the proposed pharmacological intervention, including its 
probable effectiveness, acceptability, treatment-emergent 
adverse effects, and drug interactions.
3. Obtain the advice of another prescribing clinician (and 
possibly a specialist pharmacist) with greater experience 
or expertise if the medicine to be used does not have an 
extensive evidence base to support its use for the proposed 
indication, or if you have particular concerns, or if you feel 
insufficiently expert in this field.
4. Consider the anticipated risks and benefits of treatment, 
giving particular thought in vulnerable groups such as 
children and adolescents, women of child-bearing age, 
elderly patients, physically ill patients, and patients with 
impaired insight and judgement; and document your 
thoughts on the likely balance of risk and benefit.
5. Explain fully the anticipated benefits and potential risks of 
the proposed medication to the patient (and if possible their 
relative or partner) stating that the medicine will be used 
outside the restricted terms of its product licence and make 
a record of this explanation.
6. In a situation where prescribing an unlicensed medicine 
is supported by authorative guidance, describe in general 
terms why the medicine is not licensed for the proposed 
indication, but if you intend to prescribe an unlicensed 
medicine where that is not routine, provide the patient with 
a more detailed explanation.
7. Record the agreement of the patient to the proposed 
intervention. If the patient is unable to provide consent to a 
necessary treatment, document that it has not been possible 
to obtain formal consent.
8. Start the medicine at low dose and monitor its effects 
carefully. If it is well tolerated but not effective, give thought 
to cautiously increasing the dose, with further careful 
monitoring of its effects.
9. Tell other health professionals involved in the care of the 
patient that the medicine is being prescribed outside the 
terms of its licence and encourage them to discuss their 
observations of its beneficial and untoward effects.
10. If the medicine has no beneficial effects or the emergent risks 
and hazards outweigh the benefits, withdraw it (generally, 
best done gradually) and document the reasons why it is 
being withdrawn. If there is a persistent need for further 
treatment, consider possible alternatives (using the process 
described above) and after a suitable ‘wash-out’ cautiously 
introduce the next medicine. 
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What represents 
licensed and 
unlicensed prescribing?
In the UK, medicines receive a market authorisation (previously 
called a product licence) through arrangements determined by the 
Human Medicines Regulations 2012 and implemented through the 
Medicines and Healthcare products Regulatory Agency with regard to 
European Union authorisation regulations made under the European 
Communities Act 1972. When a pharmaceutical company wishes 
to receive an authorisation for a medicine, it submits a Summary of 
Product Characteristics (SPC) to the European Medicines Agency, 
describing how the product might be used for a specific treatment, 
based on conducted clinical trials. An approved SPC forms the basis 
of the patient information leaflet (‘package insert’) that accompanies 
the medicine. Prescribing for a ‘licensed application’ occurs when the 
prescription is within the terms (indication, dosage, etc.) described 
within the market authorisation: prescribing for an ‘unlicensed 
application’ occurs when the medicine is prescribed outside those 
terms. The doses, indications, cautions, contraindications and 
side-effects of a particular medicine provided in the British National 
Formulary (BNF) reflect the authorisation and SPC, but also take 
account of guidance and advice from professional bodies and 
expert clinicians. Access to an online version of the BNF is currently 
available by registering through www.medicinescomplete.com/about/
subscribe.htm. 
Regulations relating to drug licensing vary across countries. The 
manner in which countries deal with the unlicensed use of medicines is 
not harmonised across the European Union, and some member states 
have passed legislation that promotes unlicensed use of medicines 
on economic grounds (Dooms et al, 2017). Since 1994 in France, 
an autorisations temporaires d’utilisation (temporary authorisations 
for use) procedure has provided an exceptional measure for making 
medicinal products available before formal marketing authorisation, 
in situations where there is a genuine public health need (as is cur-
rently the case for baclofen in the treatment of alcohol dependence). 
In the USA, the US Food and Drug Administration (FDA) approves 
new medicines that are shown to be safe and effective for specific 
indications, but it does not control or restrict how medicines are pre-
scribed once they become available: unlicensed or ‘off-label’ use is 
when a drug is prescribed for an indication that has not received FDA 
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approval (Wittich et al, 2012). By contrast, in Australia, an unlicensed 
application is a medicine, formulation or dosage of medicine that has 
not been evaluated or approved and not entered on the Australian 
Register of Therapeutic Goods (Gazarian et al, 2006). 
New indications for existing treatments appear regularly, and what is 
unlicensed use one month may come within the terms of a revised 
marketing authorisation the next, so becoming a licensed application. 
However, the absence of a licence does not necessarily indicate 
an absence of evidence for the proposed intervention: for exam-
ple, sertraline has efficacy in acute treatment of generalised anxiety 
disorder but is not licensed for that indication (even though it is rec-
ommended for treating the condition by the National Institute for 
Health and Care Excellence (2011)). Conversely, prescription within 
the terms of a licence is no guarantee of either safety or efficacy: for 
example, there may be troublesome pharmacokinetic interactions 
between two drugs, each prescribed for a licensed application. Use 
of a drug for an unlicensed application does not necessarily imply a 
greater safety hazard, and there are many instances where prescribing 
for an unlicensed application is uncontroversial and probably advan-
tageous (e.g. current prescriptions of venlafaxine in post-traumatic 
stress disorder or asenapine in schizophrenia). A number of factors 
influence whether a drug gains market authorisation; drugs that are 
‘off patent’ or in orphan areas are unlikely to gain new licences for an 
indication, even though there may be good evidence for their use in 
a specific condition. By contrast, a new formulation of a drug may be 
developed and have potential clinical advantages, but its authorisation 
may not include all the listed indications of an earlier formulation. 
When a drug first becomes available for clinical use, data relating to its 
potential application in young and elderly patients are extremely limited 
and consequently most prescribing for children and adolescents or 
for the elderly is for unlicensed applications. Pharmaceutical compa-
nies are strongly encouraged by regulatory authorities to undertake 
supplementary studies in children and adolescents, but there are no 
statutory requirements for drugs to be tested in these age groups. 
Modification of an existing product licence is a complex and costly 
process, so for commercial reasons pharmaceutical companies may 
be reluctant to pursue authorisation for potential additional indications, 
even when there is sufficient evidence of efficacy and safety from 
clinical trials. Pharmaceutical companies are also censured strongly 
if found to promote their products outside the terms of the market 
authorisation, although companies can distribute peer-reviewed arti-
cles about off-label use upon request by a prescribing physician 
(Wittich et al, 2012). 
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Five forms of unlicensed prescribing (‘the five Ds’: demographic, 
disorder, dosage, duration, domain) are recognised. 
1 Demographic. The age of a patient may lie outside the recom-
mended range, with most medicines being evaluated during 
clinical trial programmes in patients aged between 18 and 65 
years; and most medicines are not licensed for use in pregnant 
or breastfeeding women. 
2 Disorder. A medicine may be prescribed for a condition other 
than that or those described within the SPC and market authori-
sation, for example the use of clozapine in a patient with a primary 
affective disorder. 
3 Dosage. The prescribed dosage may be higher than recom-
mended, for example a prescription of phenelzine at a dosage 
of 90 mg/day for an out-patient or escitalopram at a dosage 
exceeding 20 mg/day. Differing generic formulations of a drug 
may have varying maximum dosages, and only some formula-
tions (e.g. extended-release versions) of particular drugs may 
be licensed for certain indications. 
4 Duration. A prescription may be for a longer period than is 
recommended, for example prescriptions of benzodiazepine 
hypnotics for more than 4 weeks. 
5 Domain. A drug may be licensed in one country but not another, 
for example quetiapine is licensed for treatment of generalised 
anxiety disorder in Australia but not in the UK.
A patient may therefore rather absurdly move from undergoing treat-
ment for a licensed application to an unlicensed application if the 
diagnosis is refined, if she becomes pregnant, when she crosses an 
age threshold, moves from in-patient to out-patient status, or crosses 
a geographical border. It is probably helpful to conceptualise pre-
scriptions as being on a spectrum, some being ‘within-label’, others 
‘near-label’, and some ‘very far off-label’. 
Prescribing for unlicensed applications is frequent in all psychiatric 
specialties and in many countries (Baldwin & Kosky, 2007). Prescribing 
for unlicensed applications is also common in general practice (Ekins-
Daukes et al, 2005), general medicine (Radley et al, 2006), paediatrics 
Types of unlicensed 
prescribing and 
possible motivations
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(Ufer et al, 2004; Cuzzolin et al, 2006; Morales-Carpi et al, 2010) 
and palliative care (Culshaw et al, 2013). Several factors are relevant 
(Wittich et al, 2012). 
 z Probably the most common circumstance is when there is a 
persisting need for treatment and previous licensed medicines 
have proved either ineffective or poorly tolerated. 
 z A medicine may be known to be generally safe and effective in 
a broad patient population, but not approved for the treatment 
of a particular subgroup of patients. 
 z Sometimes, a clinician may wish to avoid potential hazards 
associated with polypharmacy by choosing to prescribe one 
medication to treat two or more comorbid conditions even though 
the chosen medicine is approved for treating only one of the 
conditions (e.g. sertraline to treat coexisting major depression 
and generalised anxiety disorder). 
 z A serious or life-threatening condition might impel a clinician to 
recommend a treatment that seems logical even though not 
licensed for that indication.
 z A cost-conscious clinician might prefer to prescribe an unlicensed 
medication over a licensed medicine with a similar mechanism 
of action, comparable tolerability and efficacy, but differing 
pharmacokinetic properties and lower cost. 
 z Inadvertent off-label prescribing might occur when a pharma-
cist dispenses a medicine produced by another manufacturer 
for which the formulation has a lower licensed maximum daily 
dosage than the previously dispensed medicine. 
 z Finally, a clinician might feel impelled to prescribe for an unli-
censed application if a patient declines treatment with medicines 
that have a licence for the condition.
College Report CR21010
Many authors contend that prescribing for an unlicensed indication 
can represent a thoughtful and often necessary part of clinical practice 
(Anonymous, 1992; American Academy of Pediatrics, 2002; Gazarian 
et al, 2006; Baldwin & Kosky, 2007). Others have argued similarly 
that it is usually uncontroversial and may enhance clinical outcomes 
(Healy & Nutt, 1998), and that the benefits typically outweigh any 
risks (Tan et al, 2004). Prescribing a medicine solely within the terms 
of its product licence may not necessarily represent its best use in 
practice (Cohen, 2001). 
However, not all authors are so positive. For example, an expert 
panel review (based on the RAND/UCLA Appropriateness Method) 
of antipsychotic prescriptions for insomnia, anxiety, post-traumatic 
stress disorder or dementia (involving 29 scenarios for each drug) in 
69 823 US veterans judged that 60% of prescriptions were probably 
inappropriate (Painter et al, 2017). Furthermore, awareness of potential 
associated hazards associated with off-label prescriptions is often 
limited (Ekins-Daukes et al, 2005), despite evidence that this form 
of prescribing can raise clinical and ethical concerns, and may have 
potential legal consequences (Collier, 1999; Blum, 2002; Neubert 
et al, 2004; Bartoli et al, 2015). Unlicensed use of medicines in chil-
dren has been associated with both an increased incidence and a 
greater seriousness of adverse drug reactions (European Medicines 
Agency, 2004). 
Several groups have therefore sought to develop mechanisms for 
ensuring the appropriateness of off-label prescribing (Ansani et al, 
2006; Gazarian et al, 2006; Royal College of Psychiatrists, 2007; 
General Medical Council, 2013; Sharma et al, 2016; Dooms et al, 
2017). A balance must be struck between undue therapeutic con-
servatism and wilfully cavalier innovation, and between the duty to 
promote the health of individual patients and the desire to extend sci-
entific knowledge and optimise clinical practice (Baldwin et al, 2015). 
It is important that any proposed intervention appears reasonable 
to medical peers and can withstand logical analysis, which implies 
that doctors have considered the anticipated risks and benefits of 
various treatment options, with regard to the supporting evidence 
base, patient preference and the nature of the clinical case (Haynes 
et al, 2002).
Potential benefits 
and risks
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In the UK, the Medicines Act 1968 provides exemptions that enable 
doctors to use or advise the use of licensed medicines outside the 
recommendations of the licence, and to override the warnings and 
precautions given in the licence. However, in these situations (as in 
other aspects of medical practice) the doctor must be able to justify 
this action in accordance with a respectable, responsible body of 
professional opinion. In contested practice, the recommendations 
of regulatory authorities and professional bodies will be examined to 
make informed decisions about potential culpability. In the area of 
psychiatric practice, suitable authorities could include the General 
Medical Council (GMC), the Royal College of Psychiatrists, the 
Royal College of Paediatrics and Child Health (for psychotropic drug 
prescribing in children and adolescents) and the BAP. 
In its 2013 guidance the GMC stated, 
‘You should usually prescribe licensed medicines in accordance with the 
terms of their licence. However, you may prescribe unlicensed medicines 
where, on the basis of an assessment of the individual patient, you 
conclude, for medical reasons, that it is necessary to do so to meet the 
specific needs of the patient’ (para. 68). 
It continues: 
‘When prescribing an unlicensed medicine you must: (a) be satisfied 
that there is sufficient evidence or experience of using the medicine to 
demonstrate its safety and efficacy; (b) take responsibility for prescribing 
the medicine and for overseeing the patient’s care, monitoring, and any 
follow up treatment, or ensure that arrangements are made for another 
suitable doctor to do so; (c) make a clear, accurate and legible record 
of all medicines prescribed and, where you are not following common 
practice, your reasons for prescribing an unlicensed medicine’ (para. 70). 
Later paragraphs in the GMC guidance (paras. 71–73) state, ‘You 
must give patients (or their parents or carers) sufficient information 
about the medicines you propose to prescribe to allow them to make 
an informed decision’; continuing, ‘[…] where prescribing unlicensed 
medicines is supported by authoritative clinical guidance, it may be 
sufficient to describe in general terms why the medicine is not licensed 
for the proposed use or patient population’; and, ‘if you intend to 
prescribe unlicensed medicines where that is not routine or if there 
are suitably licensed alternatives available, you should explain this to 
the patient, and your reasons for doing so’. 
Guidance on 
unlicensed prescribing
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There is no legal requirement to disclose off-label use of a drug to a 
patient, but such disclosure has been advocated strongly (Frank et al, 
2008; Wilkes & Johns, 2008) and the GMC guidance recommends 
that the decision to prescribe an unlicensed medicine in preference 
to a licensed alternative should be accompanied by an explanation 
to the patient. Any risk of increased liability relating to off-label pre-
scribing may be mitigated if the prescribing physician is well informed 
about the product, bases its use on a firm scientific rationale and 
sound medical advice, and maintains records of the product’s use 
and effects (Fugh-Berman & Melnick, 2008). Again, the GMC guid-
ance emphasises both the need to be familiar with the evidence for 
the safety and efficacy of the proposed unlicensed application, and 
the need to document the unlicensed nature of the prescription and 
its utility in practice (General Medical Council, 2013). 
Guidance from the Royal College of Paediatrics and Child Health 
states that where available ‘an appropriate licensed preparation should 
be prescribed and supplied in preference to an unlicensed prepara-
tion’ (Fox & Sammons, 2013). However, the Medicines for Children 
guidance highlights situations when off-label prescribing may be 
safe and acceptable and the best choice for a patient – such as the 
medicine being formulated in a way which can be taken more easily 
by a child or because the unlicensed medicine is safer than a licensed 
one (Medicines for Children, 2015). In a position statement, the BAP 
offers guidance on the prescribing of psychotropic medication to 
children and adolescents:
‘Prescribing an off-label medicine may have advantages over a licensed 
one. Hence, licensed drugs and formulations should not always be pre-
scribed and supplied in preference to an off-label drug or formulation. 
A prescribing decision (including a decision not to prescribe) should 
incorporate knowledge of the overall evidence base and the needs of 
the individual child’ (Sharma et al, 2016: p. 420). 
The BAP guidance also states, ‘When the evidence base for an 
off-label medication is lacking or the benefit/risk profile appears 
potentially unfavourable, obtain a second opinion from another doctor 
(and perhaps another member of the multidisciplinary team) before 
prescribing’; and, ‘Explain the potential benefits and side effects to 
the patient and their parents/carers and document this discussion’ 
(Sharma et al, 2016: p. 420). As with the GMC guidance, the BAP 
position statement is clear that unlicensed prescribing should be 
based on sound knowledge and accompanied by a documented 
record of the explanation to the family. 
In 2007, the Royal College of Psychiatrists’ report CR142 included 
ten recommendations for a suggested procedure when prescribing 
off-label. The College’s Psychopharmacology Committee and rep-
resentatives from the BAP have examined these recommendations 
and have considered both accumulating evidence on licensed and 
unlicensed prescribing and guidance from other organisations. Many 
authorities agree that prescription of a drug outside the narrow terms 
of its market authorisation can be an appropriate part of the overall 
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management of individual patients: and the College supports this 
aspect of clinical practice, when it is in the best interests of a patient. 
A correct balance must be struck between the extremes of restric-
tive conservatism that may hinder good clinical outcomes and wilful 
experimentation that could put some patients at unnecessary risk. 
We have revised the original recommendations to take account of 
recent developments, while striving to ensure their practicability within 
current psychiatric practice (see pp. 4–5). 
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